These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27854009)

  • 21. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction.
    Gronda E; Francis D; Zannad F; Hamm C; Brugada J; Vanoli E
    J Cardiovasc Med (Hagerstown); 2017 Sep; 18(9):641-649. PubMed ID: 28737621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baroreflex activation for the treatment of heart failure.
    Sabbah HN
    Curr Cardiol Rep; 2012 Jun; 14(3):326-33. PubMed ID: 22528555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Baroreflex activation therapy. A novel interventional approach to treat heart failure with reduced ejection fraction].
    Halbach M; Fritz T; Madershahian N; Pfister R; Reuter H
    Herz; 2015 Nov; 40(7):959-65. PubMed ID: 26525523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Baroreflex ActivationTherapy for Heart Failure].
    Xu Y; Yang YJ; Guo J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):717-721. PubMed ID: 36065707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial.
    Ghotbi AA; Sander M; Køber L; Philbert BT; Gustafsson F; Hagemann C; Kjær A; Jacobsen PK
    PLoS One; 2015; 10(9):e0138124. PubMed ID: 26382243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.
    Zile MR; Abraham WT; Lindenfeld J; Weaver FA; Zannad F; Graves T; Rogers T; Galle EG
    Am Heart J; 2018 Oct; 204():139-150. PubMed ID: 30118942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autonomic regulation therapy suppresses quantitative T-wave alternans and improves baroreflex sensitivity in patients with heart failure enrolled in the ANTHEM-HF study.
    Libbus I; Nearing BD; Amurthur B; KenKnight BH; Verrier RL
    Heart Rhythm; 2016 Mar; 13(3):721-8. PubMed ID: 26601770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autonomic Modulation in Heart Failure: Ready for Prime Time?
    Dunlap ME; Bhardwaj A; Hauptman PJ
    Curr Cardiol Rep; 2015 Nov; 17(11):103. PubMed ID: 26384110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients.
    Mann JA; Abraham WT
    Curr Heart Fail Rep; 2019 Feb; 16(1):38-46. PubMed ID: 30762177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].
    Wallbach M; Koziolek MJ; Wachter R
    Internist (Berl); 2018 Oct; 59(10):1011-1020. PubMed ID: 30182192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure.
    Dini FL; Fontanive P; Buralli S; Panicucci E; Andreini D; Conti U; De Tommasi SM
    Int J Cardiol; 2009 Aug; 136(2):144-50. PubMed ID: 18649955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction.
    Halbach M; Hickethier T; Madershahian N; Müller-Ehmsen J
    Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1465-9. PubMed ID: 25382103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
    Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure.
    Gronda E; Brambilla G; Seravalle G; Maloberti A; Cairo M; Costantino G; Lovett E; Vanoli E; Mancia G; Grassi G
    Clin Res Cardiol; 2016 Oct; 105(10):838-46. PubMed ID: 27120329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deep and future insights into neuromodulation therapies for heart failure.
    Kishi T
    J Cardiol; 2016 Nov; 68(5):368-372. PubMed ID: 27293020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial.
    Huijts M; van Oostenbrugge RJ; Duits A; Burkard T; Muzzarelli S; Maeder MT; Schindler R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Jun; 15(6):699-707. PubMed ID: 23384944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central command: control of cardiac sympathetic and vagal efferent nerve activity and the arterial baroreflex during spontaneous motor behaviour in animals.
    Matsukawa K
    Exp Physiol; 2012 Jan; 97(1):20-8. PubMed ID: 21984731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.